Paraparesis due to exacerbation of preexisting spinal pseudoarthrosis following infliximab therapy for advanced ankylosing spondylitis

2006 ◽  
Vol 6 (3) ◽  
pp. 325-329 ◽  
Author(s):  
Hironobu Sakaura ◽  
Noboru Hosono ◽  
Yoshihiro Mukai ◽  
Ryutaro Fujii ◽  
Hideki Yoshikawa
Keyword(s):  
Ankylosing Spondylitis ◽  
Infliximab Therapy

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

2008 ◽  
Vol 58 (10) ◽  
pp. 3063-3070 ◽  
Author(s):  
Désirée van der Heijde ◽  
Robert Landewé ◽  
Xenofon Baraliakos ◽  
Harry Houben ◽  
Astrid van Tubergen ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Infliximab Therapy ◽  
Radiographic Findings

Infliximab Therapy for Inflammatory Discitis in Ankylosing Spondylitis

2012 ◽  
Vol 18 (2) ◽  
pp. 109-110 ◽  
Author(s):  
Nilay Joshi ◽  
Amit Nautiyal ◽  
Tom Walton
Keyword(s):  
Ankylosing Spondylitis ◽  
Infliximab Therapy

Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis

2008 ◽  
Vol 27 (11) ◽  
pp. 1429-1435 ◽  
Author(s):  
Consuelo Romero-Sánchez ◽  
William H. Robinson ◽  
Beren H. Tomooka ◽  
John Londoño ◽  
Rafael Valle-Oñate ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Acute Phase ◽  
Infliximab Therapy ◽  
Acute Phase Reactants

scholarly journals Henoch-Schönlein Purpura in a Patient with Ankylosing Spondylitis after Infliximab Therapy

2013 ◽  
Vol 84 (5) ◽  
pp. 764 ◽  
Author(s):  
Woo-Jin Jung ◽  
Yoon-Jeong Nam ◽  
Seung-Geun Lee ◽  
Ji-Min Kim ◽  
Margaret Song ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Infliximab Therapy ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

scholarly journals Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Mireia Moreno ◽  
◽  
Jordi Gratacós ◽  
Vicenç Torrente-Segarra ◽  
Raimon Sanmarti ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Clinical Remission ◽  
Infliximab Therapy

scholarly journals Effect of Infliximab Therapy in Functional Improvement in Patients with Ankylosing Spondylitis

2017 ◽  
Vol 28 (2) ◽  
pp. 59-63
Author(s):  
Ambar Konar ◽  
Debayan Ghorai ◽  
Aniketa Banerjee
Keyword(s):  
Ankylosing Spondylitis ◽  
Postgraduate Medical Education ◽  
Controlled Trial ◽  
Functional Limitation ◽  
Rehabilitation Program ◽  
Infliximab Therapy ◽  
Functional Improvement ◽  
Control Group ◽  
Group I ◽  
Asas Criteria

ABSTRACT Introduction Ankylosing spondylitis (AS), one of the spondyloarthropathies predominantly affecting younger people, is notorious for morbidity with pain, functional impairment, and disability. Infliximab, a chimeric tumor necrosis factor (TNF) alpha inhibitor, has been proven as a safe and effective biologic in respect to improvement in clinical and radiological parameters in AS. This study is a humble attempt to look for disability limitations by infliximab therapy in patients with AS. Aims and objectives To look for functional improvement in AS patients treated with Infliximab in comparison with control group who were treated conservatively. Materials and methods A randomized controlled trial was done in the Department of Physical Medicine and Rehabilitation, Institute of Postgraduate Medical Education & Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India, from December 2015 to May 2017, recruiting 20 AS patients who fulfilled the Assessment of SpondyloArthritis International Society (ASAS) criteria and had significant functional limitation. After Ethics Committee clearance, two groups were made randomly. Both groups I and II were included in the rehabilitation program. Group I, in addition, received injection infliximab on days 0, 14, and 42. Assessment by the Bath ankylosing spondylitis functional index (BASFI) and visual analog scale (VAS) for lower back pain was done before intervention and 2, 6, 12 weeks after initiation of treatment. Results Statistically significant positive outcome difference was seen in the first group in comparison with control group based on both outcome parameters. Conclusion Infliximab is a safe and highly efficacious biologic therapy in limiting disability in AS patients when treated early. How to cite this article Konar A, Pramanik R, Ghorai D, Banerjee A. Effect of Infliximab Therapy in Functional Improvement in Patients with Ankylosing Spondylitis. Indian J Phy Med Rehab 2017;28(2):59-63.

Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis

2007 ◽  
Vol 187 (9) ◽  
pp. 524-526 ◽  
Author(s):  
Gerard Ozorio ◽  
Bruce McGarity ◽  
Haesung Bak ◽  
Andrew S Jordan ◽  
Henry Lau ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Autoimmune Hepatitis ◽  
Infliximab Therapy
Sign in / Sign up

Export Citation Format

Share Document